AFM
ACAD icon

Anson Funds Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Anson Funds Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-112,650
Closed -$2.63M – 337
2021
Q4 		$2.63M Buy
+112,650
New +$2.27M 0.26% 81

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Anson Funds Management's ACAD Position: Q1 2022 in Review

Anson Funds Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2022, closing a stake of 112,650 shares — an estimated $2.63M sold.

Anson Funds Management first reported a position in ACAD in Q4 2021 and held it in 1 quarter. The position peaked at $2.63M in Q4 2021. 263 funds tracked by Wall St. Rank hold ACAD as of Q1 2022.

  • Anson Funds Management reported no remaining Acadia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 112,650 Acadia Pharmaceuticals shares in Q1 2022, an estimated $2.63M.
  • Anson Funds Management first reported a position in Acadia Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Anson Funds Management's Acadia Pharmaceuticals position peaked at $2.63M in Q4 2021.
  • 263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.